{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:55:25Z","timestamp":1772121325591,"version":"3.50.1"},"reference-count":13,"publisher":"JLE","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.nephro.2017.02.006","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T02:16:04Z","timestamp":1496283364000},"page":"S43-S45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Dual renin\u2013angiotensin system blockade for nephroprotection"],"prefix":"10.1684","volume":"13","author":[{"given":"Piero","family":"Ruggenenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","reference":[{"key":"10.1016\/j.nephro.2017.02.006_bib0070","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1681\/ASN.2012040390","article-title":"Mechanisms and treatment of CKD","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.02.006_bib0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2\u00a0diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.nephro.2017.02.006_bib0080","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.02.006_bib0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00467-016-3495-1","article-title":"Achieving remission of proteinuria in childhood CKD","volume":"32","author":"Ruggenenti","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nephro.2017.02.006_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000381480","article-title":"A multidrug, antiproteinuric approach to Alport syndrome: a ten-year cohort study","volume":"130","author":"Daina","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.nephro.2017.02.006_bib0095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1470320310392097","article-title":"Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2\u00a0diabetes mellitus rats","volume":"12","author":"Rao","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.nephro.2017.02.006_bib0100","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ontarget study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.nephro.2017.02.006_bib0105","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2\u00a0diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.006_bib0110","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.006_bib0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2\u00a0diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nephro.2017.02.006_bib0120","first-page":"153A","article-title":"Relative renoprotective effect of ace inhibitors (acei), angiotensin ii antagonists (ata), acei and ata combination and dihydropyridine calcium channel blockers (dccbs) in overt nephropathy of type 2\u00a0diabetes","volume":"12","author":"Parvanova","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nephro.2017.02.006_bib0125","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1046\/j.1523-1755.2003.00832.x","article-title":"Effects of combined ace inhibitor and angiotensin ii antagonist treatment in human chronic nephropathies","volume":"63","author":"Campbell","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.nephro.2017.02.006_bib0130","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5301\/JN.2011.7763","article-title":"The Remission Clinic approach to halt the progression of kidney disease","volume":"24","author":"Remission Clinic Task Force","year":"2011","journal-title":"J Nephrol"}],"container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769725517300470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.jle.com\/10.1016\/j.nephro.2017.02.006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T11:42:15Z","timestamp":1741174935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769725517300470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":13,"alternative-id":["S1769725517300470"],"URL":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.006","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727685242.793533080","asserted-by":"object"}]},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual renin\u2013angiotensin system blockade for nephroprotection","name":"articletitle","label":"Article Title"},{"value":"N\u00e9phrologie & Th\u00e9rapeutique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nephro.2017.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 francophone de n\u00e9phrologie, dialyse et transplantation. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}